NYSE:ABT
Abbott Labs (ABT)
97.34
+0.65 (0.67%)
as of Oct 2, 2026, 6:46:12 pm Market Open.
354 watching
Financials 
Technical Analysis 0
BUY
She still thinks it is as good long term investment in this space. Their testing kits are being widely deployed. Testing will remain an important factor in this COVID situation. They will still be well positioned. In their medical devices business they have a lot of new products that will be launched. The dividend is attractive and is increased annually. She sees good long term value.
Christine PooleOwned
biotechnologypharmaceutical
BUY
ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly This medical device company has has been front and centre during the pandemic -- providing six COVID-19 test kits -- including one now that provides results in 15 minutes. The company's other products help patients with chronic cardiovascular, pulminary, and diabetic issues. The company is launching a new non-finger poking glucose monitoring device -- a game changer. A recent pullback in the share price gives an opportunity to enter with reasonable upside. We would trade this with a $97 stop-loss looking to achieve $128 -- 17% upside. Yield 1.34% (Analysts’ price target is $115.12)
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
Christine PooleOwned
biotechnologypharmaceutical
WATCH
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
biotechnologypharmaceutical
TOP PICK
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
Christine PooleOwned
biotechnologypharmaceutical
COMMENT
ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
Christine PooleOwned
biotechnologypharmaceutical
BUY
It was a pharma, but spun that operation off. What's left is a company in medical diagnostics. ABT bought two medical companies to build on that. A very good company with a long string of growing dividend payments, like 35 years. His only knock is that its PE has run, so watch that.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick Jan 10/19, Up 25%) A diversified healthcare company that's done well. They sell generic drugs to higher-growth EM (40% of revenues); adult and child nutritional products; and medical products which is showing profit momentum driven by product launches. Aging demographics favour ABT. They don't suffer US drug pricing issues, either. They've increased their dividend for the last 47 years.
Christine PooleOwned
biotechnologypharmaceutical
TOP PICK
Diversified healthcare company, a space she likes. Not impacted by focus on drug pricing. Sell generics to emerging markets. Also a nutritional business and medical devices, which are growing. Has increased dividend 46-47 years in a row. Yield is 1.50%. (Analysts’ price target is $92.87)
Christine PooleOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
